Skip to main content

Table 1 Model input parameters

From: Five-year cost-effectiveness analysis of the European Fans in Training (EuroFIT) physical activity intervention for men versus no intervention

PARAMETERS FOR THE BASE CASE ANALYSIS
 Values*Distribution for probabilistic sensitivity analysisSource
Physical activity (transition probabilities at the end of each cycle of 12 months)
EuroFIT
 Inactive to Inactive0.18Beta (α = 4.0, β = 17.0)EuroFIT RCT [20]
 Inactive to Moderately active0.054Beta (α = 0.34, β = 5.7)EuroFIT RCT [20]
 Inactive to Recommended activity0.71Beta (α = 59.4, β = 19.6)EuroFIT RCT [20]
 Moderately active to Moderately active0.042Beta (α = 0.09, β = 1.9)EuroFIT RCT [20]
 Moderately active to Inactive0.085Beta (α = 0.44, β = 4.56)EuroFIT RCT [20]
 Moderately active to Recommended activity0.82Beta (α = 33.8, β = 5.2)EuroFIT RCT [20]
 Recommended activity to Recommended Activity0.89Beta (α = 357.9, β = 26.1)EuroFIT RCT [20]
 Recommended activity to Inactive0.042Beta (α = 0.83, β = 18.2)EuroFIT RCT [20]
 Recommended activity to Moderately active0.023Beta (α = 0.24, β = 9.8)EuroFIT RCT [20]
No intervention
 Inactive to Inactive0.33Beta (α = 11.5, β = 21.5)EuroFIT RCT [20]
 Inactive to Moderately active0.12Beta (α = 1.6, β = 10.4)EuroFIT RCT [20]
 Inactive to Recommended activity0.49Beta (α = 25.0, β = 23.0)EuroFIT RCT [20]
 Moderately active to Moderately active0.17Beta (α = 1.5, β = 6.6)EuroFIT RCT [20]
 Moderately active to Inactive0.19Beta (α = 2.1, β = 8.0)EuroFIT RCT [20]
 Moderately active to Recommended activity0.58Beta (α = 16.6, β = 10.4)EuroFIT RCT [20]
 Recommended activity to Recommended Activity0.80Beta (α = 290.7, β = 58.3)EuroFIT RCT [20]
 Recommended activity to Inactive0.10Beta (α = 4.2, β = 37.8)EuroFIT RCT [20]
 Recommended activity to Moderately active0.064Beta (α = 1.9, β = 26.1)EuroFIT RCT [20]
Health conditions (transition probabilities at the end of each cycle of 12 months)
 Inactive to colorectal cancer0.015FixedCOSM study [30, 31]
 Inactive to heart diseases0.011FixedMeta-analysis; SALLS study [30, 32,33,34]
 Inactive to Type 2 diabetes0.005FixedEPIC-Interact study and epidemiological study [33, 35, 36]
 Inactive to stroke0.0046FixedARIC study [37]
 Inactive to depression0.010FixedMeta-analysis; Health survey for England and Scotland [34, 35, 38]
 Moderately active to colorectal cancer0.011FixedCOSM study [30, 31]
 Moderately active to heart disease0.009FixedMeta-analysis; SALLS study [30, 32,33,34]
 Moderately active to Type 2 diabetes0.0038FixedEPIC-Interact study; epidemiological study [33, 35, 36]
 Moderately active to stroke0.0033FixedARIC study [37]
 Moderately active to depression0.0094FixedMeta-analysis; Health survey for England and Scotland [34, 35, 38]
 Recommended activity to colorectal cancer0.0096FixedCOSM study [30, 31]
 Recommended activity to heart disease0.008FixedMeta-analysis; SALLS study [30, 32,33,34]
 Recommended activity to Type 2 diabetes0.0033FixedEPIC-Interact study; epidemiological study [33, 35, 36]
 Recommended activity to stroke0.0029FixedARIC study [37]
 Recommended activity to depression0.0092FixedMeta-analysis; Health survey for England and Scotland [34, 38, 39]
Mortality (transition probabilities at the end of each cycle of 12 months)
 Inactive to death0.016FixedMeta-analysis; epidemiological study [73, 74, 75, 76]
 Moderately active to death0.012FixedMeta-analysis; epidemiological study [73, 74, 75, 76]
 Recommended activity to death0.010FixedMeta-analysis; epidemiological study [73, 74, 75, 76]
 Colorectal cancer to death0.092FixedInternational Cancer Benchmarking partnership registries [40]
 Coronary heart disease to death0.002FixedWONDER registry [41]
 Type 2 diabetes to death0.015FixedZODIAC study [42]
 Stroke to death0.400FixedMONICA registry [43]
 Depression to death0.030FixedSTIRLING registry [44]
Utility values
 Inactive – Base case0.909Beta (α = 3.0, β = 0.38)EuroFIT RCT [20]
 Moderately active – Base case0.919Beta (α = 5.1, β = 0.51)EuroFIT RCT [20]
 Recommended activity – Base case0.922Beta (α = 5.1, β = 0.43)EuroFIT RCT [20]
 Colorectal cancer0.786FixedSystematic review [45]
 Coronary hearth disease0.735FixedLongitudinal survey [46]
 Stroke0.62FixedLongitudinal survey [47]
 Type 2 diabetes0.785FixedSystematic review [48]
 Depression0.57FixedSystematic review [49]
Annual costs per person according to the societal perspective (€ 2017)
 Inactive2436Gamma (shape = 0.19, scale = 12,658)EuroFIT RCT [20]
 Moderately active1506Gamma (shape = 0.22, scale = 6920)EuroFIT RCT [20]
 Recommended activity1997Gamma (shape = 0.24, scale = 8222)EuroFIT RCT [20]
 Colorectal cancer34,085FixedCross sectional study; Health insurance registry [50, 51]
 Coronary heart disease5239FixedEconomic burden [52]
 Type 2 diabetes5907FixedEconomic burden [53]
Stroke24,979FixedEconomic burden [54]
 Depression6819FixedCost-effectiveness analysis [55]
 EuroFIT program260FixedEuroFIT RCT [20]
PARAMETERS FOR THE SENSITIVITY ANALYSES
Utility values
 Inactive – Literature utilities0.80FixedEconomic evaluation [24]
 Moderately active – Literature utilities0.87FixedEconomic evaluation [24]
 Recommended activity – Literature utilities0.91FixedEconomic evaluation [24]
Annual costs per person according to the healthcare perspective (€ 2017)
 Inactive1107Gamma (shape = 0.10, scale = 10,924)EuroFIT RCT [20]
 Moderately active594Gamma (shape = 0.35, scale = 1707)EuroFIT RCT [20]
 Recommended activity747Gamma (shape = 0.19, scale = 4040)EuroFIT RCT [20]
 Colorectal cancer25,346FixedCross sectional study; Health insurance registry [50, 51]
 Coronary heart disease1954FixedEconomic burden [52]
 Type 2 diabetes3089FixedEconomic burden [53]
 Stroke18,750FixedEconomic burden [54]
 Depression966FixedCost-effectiveness analysis [55]
  1. *Values represent probabilities, mean utilities or mean costs